ZUG, Switzerland and CAMBRIDGE, Mass., June 13, 2023 (GLOBE NEWSWIRE) — CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in a fireside chat at the 44th Annual Goldman Sachs Global Healthcare Conference being held from June 12th– 15th, 2023.
Fireside Chat
Presenter: Sam Kulkarni, Ph.D., Chief Executive Officer
Date: Wednesday, June 14, 2023
Time: 10:00 a.m. PT
A live webcast of the fireside chat will be available on the “Events & Presentations” page in the Investors section of the Company’s website at https://crisprtx.gcs-web.com/events. A replay of the webcast will be archived on the Company’s website for 14 days following the presentation.
About CRISPR Therapeutics
CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic partnerships with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Boston, Massachusetts and San Francisco, California, and business offices in London, United Kingdom. For more information, please visit www.crisprtx.com.
CONTACT: Investor Contact: Susan Kim +1-617-307-7503 susan.kim@crisprtx.com Media Contact: Rachel Eides +1-617-315-4493 rachel.eides@crisprtx.com
Expanding its roster of technology leaders will enhance its ability to drive innovation and deliver…
Third-party research confirms significant impact of specialty expertise on patients’ quality of life and costs…
Proven healthcare executive and life sciences strategist joins to bring groundbreaking BioFuse Multi-Tissue Welder (MTW)…
Next Generation Shaw Scalpel Receives 510(k) Clearance, Ushering in a New Era of Surgical PrecisionKALAMAZOO,…
RAHWAY, NJ / ACCESSWIRE / March 26, 2024 / The Merck Foundation, a private charitable…
NORTHAMPTON, MA / ACCESSWIRE / March 26, 2024 / Dr. Thomas Odeny grew up in…